Lundbeck nears end of Brazilian sham litigation probe

The chief investigator for Brazil’s antitrust authority has recommended dropping an investigation into Lundbeck, due to insufficient evidence the drugmaker conducted sham litigation in an abuse of dominance on the national pharmaceuticals market.

Get unlimited access to all Global Competition Review content